7 news items
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
CRNX
18 Jun 24
a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets. Enabled by data
Crinetics To Present New Data Results Of The Phase 3 PATHFNDR-2 Trial Showing Increasing Evidence Positioning Once-Daily, Oral Paltusotine As Potential First-Choice Treatment Option for Acromegaly At ENDO 2024
CRNX
3 Jun 24
at 42 months from the open-label ACROBAT Advance extension study. The data were presented today at the Endocrine Society's Annual Meeting (ENDO2024
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)
CRNX
3 Jun 24
) receptor antagonist. The results, presented at the Endocrine Society's annual meeting (ENDO2024), include initial data from the Phase 1b/2a, open-label study
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
CRNX
3 Jun 24
presented today at the Endocrine Society's Annual Meeting (ENDO2024), with findings from PATHFNDR-1
Crinetics Pharmaceuticals Announces ENDO 2024 Late-Breaking Abstracts; Were Released Earlier Than The Previously Announced Embargoed Date; More Fulsome Data Set Will Be Shared Within The Poster Presentations Scheduled To Be Presented On June 3, 2024
CRNX
22 May 24
at the Endocrine Society's annual meeting (ENDO 2024) were released earlier than the previously announced embargoed date
pmufss v93
CRNX
22 May 24
accepted for presentation at the Endocrine Society's annual meeting (ENDO 2024) were released earlier
jx3 zoo2t18
CRNX
8 May 24
-breaking abstracts, will be presented at the Endocrine Society's annual meeting
- Prev
- 1
- Next